{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000034","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.457647+00:00","generated_at":"2026-06-05T04:41:28.526742+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1","bullets":["Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.","Dr. Jenkins receives annual cash retainer of $40,000 plus committee retainers; option for 40,000 shares vesting over 1 year.","Director Margaret Dalesandro to resign effective Aug 1, 2024, citing no disagreement with company.","Dr. Jenkins brings 25+ years pharma/biotech experience including roles at Merck Serono, BMS, and as CEO of Dimension Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000034","json":"https://secwatch.observer/filing/0001516551-24-000034.json","markdown":"https://secwatch.observer/filing/0001516551-24-000034.md","text":"https://secwatch.observer/filing/0001516551-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/0001516551-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/skye-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:41:28.526742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"057ffa17f9","claim":"Margaret Dalesandro resigned as Director at Skye Bioscience, Inc..","evidence_excerpt":"Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/0001516551-24-000034-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3125c21c45","claim":"Annalisa Jenkins was appointed as Director at Skye Bioscience, Inc..","evidence_excerpt":"appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000034/0001516551-24-000034-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}